ACC Patent Committee Meeting
Market Exclusivity – FDA Considerations in Patent Product Protection Strategies
Wednesday, October 9, 2019
4:30 PM - 6:30 PM
Registration: 4:30 p.m. - 5 p.m.
Program: 5 p.m. – 6 p.m.
Networking: 6 p.m. – 6:30 p.m.
Sheppard Mullin Office
Four Embarcadero Center,
San Francisco, CA 94111
Description: Protecting a company’s substantial investment in drug and biologic discovery is key to a product’s commercial success. Market exclusivity has the potential to drive innovation for large and small molecules, and also orphan drugs and other niche drugs with a limited market. In this session, we will explore strategies for maximizing exclusivity from both a patent and FDA regulatory perspective. We also will discuss the opportunities and challenges of attaining market exclusivity from in-house attorneys at both large and small molecule companies.
Lorna Tanner: Partner, Sheppard Mullin
Allison Fulton: Partner, Sheppard Mullin
Lauren Stevens: Consultant, Global Patent Group, LLC
Leslie Robbins: Senior VP Intellectual Property, CytomX Therapeutics